+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Synaptic Dysfunction"

Fragile X Syndrome (FXS) Treatment Market Report 2026 - Product Thumbnail Image

Fragile X Syndrome (FXS) Treatment Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
From
  • 4 Results (Page 1 of 1)
Loading Indicator

The Synaptic Dysfunction market within the context of Neurology is focused on the development of treatments for neurological disorders caused by impaired synaptic transmission. These disorders can include Alzheimer's disease, Parkinson's disease, Huntington's disease, and epilepsy. Synaptic dysfunction can also be caused by genetic mutations, environmental toxins, and other factors. Treatments for these disorders typically involve drugs that target the underlying cause of the disorder, as well as therapies that aim to improve synaptic transmission. In the Synaptic Dysfunction market, there are a number of companies that are developing treatments for neurological disorders. These include AbbVie, Biogen, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Additionally, there are a number of smaller companies that are developing treatments for neurological disorders, such as Axovant Sciences, Denali Therapeutics, and Voyager Therapeutics. Show Less Read more